Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation.
Saved in:
| Title: | Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation. |
|---|---|
| Authors: | Hanf D; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany., Heining C; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany., Laaber K; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Nebelung H; Department of Radiology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Uhrig S; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Hutter B; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Jahn A; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany., Richter D; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany., Aust D; Institute of Pathology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Herbst F; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Fröhling S; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Glimm H; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Folprecht G; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Medical Department/University Cancer Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2021 Apr 22; Vol. 5. Date of Electronic Publication: 2021 Apr 22 (Print Publication: 2021). |
| Publication Type: | Case Reports; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34250401 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 <superscript>G623R</superscript> Solvent-Front Mutation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hanf+D%22">Hanf D</searchLink>; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Heining+C%22">Heining C</searchLink>; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Laaber+K%22">Laaber K</searchLink>; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Nebelung+H%22">Nebelung H</searchLink>; Department of Radiology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Uhrig+S%22">Uhrig S</searchLink>; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Hutter+B%22">Hutter B</searchLink>; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Jahn+A%22">Jahn A</searchLink>; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Richter+D%22">Richter D</searchLink>; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Aust+D%22">Aust D</searchLink>; Institute of Pathology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Herbst+F%22">Herbst F</searchLink>; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Fröhling+S%22">Fröhling S</searchLink>; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Glimm+H%22">Glimm H</searchLink>; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Folprecht+G%22">Folprecht G</searchLink>; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Medical Department/University Cancer Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2021 Apr 22; Vol. 5. <i>Date of Electronic Publication: </i>2021 Apr 22 (<i>Print Publication: </i>2021). – Name: TypePub Label: Publication Type Group: TypPub Data: Case Reports; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34250401 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/PO.20.00278 Languages: – Code: eng Text: English Titles: – TitleFull: Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hanf D – PersonEntity: Name: NameFull: Heining C – PersonEntity: Name: NameFull: Laaber K – PersonEntity: Name: NameFull: Nebelung H – PersonEntity: Name: NameFull: Uhrig S – PersonEntity: Name: NameFull: Hutter B – PersonEntity: Name: NameFull: Jahn A – PersonEntity: Name: NameFull: Richter D – PersonEntity: Name: NameFull: Aust D – PersonEntity: Name: NameFull: Herbst F – PersonEntity: Name: NameFull: Fröhling S – PersonEntity: Name: NameFull: Glimm H – PersonEntity: Name: NameFull: Folprecht G IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 04 Text: 2021 Apr 22 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 2473-4284 Numbering: – Type: volume Value: 5 Titles: – TitleFull: JCO precision oncology Type: main |
| ResultId | 1 |
